BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 21882184)

  • 1. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
    Kim TH; Park YJ; Lim JA; Ahn HY; Lee EK; Lee YJ; Kim KW; Hahn SK; Youn YK; Kim KH; Cho BY; Park DJ
    Cancer; 2012 Apr; 118(7):1764-73. PubMed ID: 21882184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
    Zhang Q; Liu SZ; Zhang Q; Guan YX; Chen QJ; Zhu QY
    Cell Physiol Biochem; 2016; 38(2):763-76. PubMed ID: 26871894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Coexistent BRAF
    Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
    Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome.
    Russo M; Malandrino P; Nicolosi ML; Manusia M; Marturano I; Trovato MA; Pellegriti G; Frasca F; Vigneri R
    Thyroid; 2014 Aug; 24(8):1267-74. PubMed ID: 24787545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Value of BRAF
    Song JY; Sun SR; Dong F; Huang T; Wu B; Zhou J
    Curr Med Sci; 2018 Oct; 38(5):785-797. PubMed ID: 30341513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
    Liu C; Chen T; Liu Z
    World J Surg Oncol; 2016 Sep; 14(1):241. PubMed ID: 27600854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.
    Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas.
    Lee JI; Jang HW; Kim SW; Kim JW; Oh YL; Chung JH
    Head Neck; 2013 Apr; 35(4):548-53. PubMed ID: 22488961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between BRAF (V600E) mutation and pathological features in PTC.
    Liu X; Yan K; Lin X; Zhao L; An W; Wang C; Liu X
    Eur Arch Otorhinolaryngol; 2014 Nov; 271(11):3041-52. PubMed ID: 24389984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer.
    Niederer-Wüst SM; Jochum W; Förbs D; Brändle M; Bilz S; Clerici T; Oettli R; Müller J; Haile SR; Ess S; Stoeckli SJ; Broglie MA
    Surgery; 2015 Jan; 157(1):119-25. PubMed ID: 25482468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
    Tufano RP; Teixeira GV; Bishop J; Carson KA; Xing M
    Medicine (Baltimore); 2012 Sep; 91(5):274-286. PubMed ID: 22932786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
    Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M; Yan C; Xiao J; Wang T; Ling R
    Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
    Xing M; Alzahrani AS; Carson KA; Viola D; Elisei R; Bendlova B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Tufano RP; Pai SI; Zeiger MA; Westra WH; Clark DP; Clifton-Bligh R; Sidransky D; Ladenson PW; Sykorova V
    JAMA; 2013 Apr; 309(14):1493-501. PubMed ID: 23571588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk and Prognostic Factors for BRAF
    Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
    Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
    Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.